REGAIN CONTROL OVER ADDICTION

Introducing the first prescription digital therapeutic for the treatment of patients with substance use disorder (SUD)

reSET® for Substance Use Disorder

Pear Therapeutics has developed reSET®, a prescription digital therapeutic to be used in conjunction with standard outpatient treatment for substance use disorder (SUD)

Patient-Facing Smartphone Application

Clinician-Facing Web Interface

reSET® as a Prescription Digital Therapeutic for Treating Substance Use Disorder

reSET® has been proven to increase abstinence from a patient’s substances of abuse during treatment and increase patient retention in treatment when used as part of an outpatient treatment program

  • reSET® was evaluated in a clinical trial of 507 patients with SUD across 10 treatment centers nation-wide over 12 weeks.*
  • Patients were randomized to either a standard treatment as usual (TAU), which consisted of intensive face-to-face counseling, or to a reduced amount of face-to-face counseling plus reSET®.*

ABSTINENCE

  • Abstinence was measured twice weekly via urine analysis, breathalyzer, and self-reports.
  • In patients who were dependent on stimulants, marijuana, cocaine, or alcohol (n=395), 58.1% of patients receiving reSET®* were abstinent in study weeks 9-12, while 29.8% of patients receiving face-to-face therapy alone were abstinent during the same time frame (p<0.01).
  • Participants who tested positive for drug use at the start of the study (n=191), 26.7% of patients receiving reSET®* were abstinent in study weeks 9-12, while 3.2% of patients receiving traditional face-to-face therapy were abstinent during the same time frame (p<0.01).
All Patients
Patients Non-Abstinent at Baseline

RETENTION

  • Patients receiving reSET® showed statistically significant improvement in retention compared to face-to-face therapy alone (p=0.0316). At the end of 12 weeks of treatment 59% of patients receiving face-to-face therapy were retained in the study compared to 67% of patients receiving reSET®.

ENGAGEMENT

  • User engagement was measured in the pivotal study by comparing the average number of reSET® modules completed each week between patients abstinent and non-abstinent throughout the 12-week study.
  • Results show how all patients remain engaged throughout the study, and interestingly, the patients that were abstinent completed more modules per week.
Modules Completed per Week
Time Spent on Modules

 

1. Campbell et al. Am J Psychiatry. 2014.
2. Hubbard et al. Psychol Addict Behav. 1997.
3. Simpson. Am J Psychiatry. 1979.
4. Zhang et al. Addiction. 2003.
ClinicalTrials.gov Identifier: NCT01104805

For more information, please contact us

Contact Us

reSET® is not yet available for sale in the United States

* Therapeutic Education System (TES), which has equivalent content to reSET®, was tested. Please see labeling for study details.